Shanghai Escugen Biotechnology Co., Ltd

This Phase 2 trial tests an experimental drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The drug targets a protein to reduce immune system attacks on the body. Researchers will compare high and low doses against …